Kadmon announced the publication of data from preclinical studies supporting its oral drug candidate, KD025, a small molecule ROCK2 inhibitor, as a potential treatment for autoimmune diseases such as systemic lupus erythematosus (SLE). The data indicated that KD025 worked to inhibit the rho-associated coiled-coil kinase 2 signaling pathway (ROCK2), reducing the development and function…
Kadmon Corporation, LLC, a biopharmaceutical company focused on autoimmune, fibrotic, metabolic diseases and the oncology field, recently announced promising preclinical data on its KD025 drug in the treatment of systemic lupus erythematosus (SLE). The data was presented in May 2015 at the American Association of Immunologists (AAI) Annual…
The Kadmon Corporation’s Phase 2 oral drug, KD025, a potent, bio-available and highly selective inhibitor of ROCK2 (Rho-associated coiled-coiled kinase 2) that can be taken orally was designed as one of its priority candidates to treat lupus through the LRxL-STAT Lupus Drug Repositioning Initiative. The selection of the drug was presented at the annual American College…